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AbstrACt
Introduction Type 1 diabetes has the potential to 
significantly impact children’s educational attainment. With 
the increase in incidence, quantifying this effect would be 
useful to assess how much additional support should be 
focused on children with type 1 diabetes in school.
Methods and analysis We will conduct a systematic 
review of all observational studies and randomised 
controlled trials, including individuals both with and 
without a diagnosis of type 1 diabetes who have 
undertaken high stakes testing at the end of compulsory 
schooling when under 18 years of age. The search will 
cover both peer-reviewed and grey literature available 
from January 2004 to January 2018. The following 
seven databases will be searched: Ovid MEDLINE (1946 
to present), Ovid MEDLINE Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid EMBASE 
(1947 to present), Thomson Reuters Web of Science, 
EBSCO Education Resources Information Center, EBSCO 
British Education Index and EBSCO Cumulative Index to 
Nursing and Allied Health Literature. Study selection and 
data extraction will be performed independently by two 
reviewers with any disagreements resolved via a third 
reviewer. The quality and risk of bias in the observational 
studies included in this review will be assessed using 
the Newcastle-Ottawa Scale. We aim to conduct a 
meta-analysis and will assess heterogeneity between 
the included studies and potential for publication bias if 
sufficient (>10) studies are included.
results and dissemination Formal ethical approval is 
not required as individual patient data will not be collected. 
Results will be disseminated through peer-reviewed 
publication and conference presentations.
PrOsPErO registration number CRD42017084078.
IntrOduCtIOn 
background
Type 1 diabetes (T1DM), also known as insu-
lin-dependent or juvenile diabetes, is an 
autoimmune disease which causes destruc-
tion of the insulin-producing beta cells in 
the pancreas, preventing the body from 
adequately regulating blood glucose levels. 
It can occur at any age but is most commonly 
diagnosed in childhood and adolescence.1 
According to the 2017 IDF Diabetes Atlas 
eighth edition, 451 million people aged 
18–99 years worldwide are estimated to have 
diabetes, of which 7%–12% are thought to 
have T1DM. The number of children diag-
nosed with T1DM is increasing annually, 
particularly in children under 15 years of 
age, with an estimated annual increase of 
approximately 3%. In 2017, there were an 
estimated 587 000 children under 15 years of 
age with T1DM worldwide, with an estimated 
96 100 new cases every year.2 In the UK, 
T1DM represents over 96% of childhood 
cases of diabetes.3 Short-term complications 
of diabetes can include hypoglycaemia, 
hyperglycaemia and ketoacidosis. Long-
term complications include heart disease, 
stroke, retinopathy, neuropathy and kidney 
disease.4 
rationale for review
The health outcomes of T1DM in children 
are well documented, but the wider psycho-
social impacts are less established, and there 
is a lack of understanding of the effects 
on educational attainment.5 These wider 
impacts are not only important in them-
selves, but also have the potential to have an 
effect on later life health outcomes through 
strengths and limitations of this study
 ► This systematic review will comprehensively evalu-
ate available literature reporting the impact of type 
1 diabetes on educational attainment in individuals 
undertaking high stakes standardised testing under 
age 18 at the end of compulsory schooling.
 ► Our findings will be reported using the recommend-
ed methods and checklist of the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses.
 ► Study selection and data extraction will be per-
formed independently by two reviewers, with any 
disagreements resolved via a third reviewer.
 ► A potential limitation of this review may be varying 
quality and high heterogeneity among available 
studies.
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mechanisms such as employment, income and social 
status.
Many patients and their families express concerns 
about the potential negative impact that T1DM may 
have on a child’s attendance at school,6 and many report 
worries about schools’ ability to support children with 
diabetes.7 Hypoglycaemia, hyperglycaemia and diabetic 
ketoacidosis as well as psychological challenges and 
reduced attendance due to illness and hospital appoint-
ments are all factors which may result in poorer educa-
tional attainment for children with T1DM compared with 
their non-diabetic counterparts.8–10 There is conflicting 
evidence as to the exact effect T1DM has on educational 
attainment and the real magnitude of this impact.6
Previous literature has focused on the effects of T1DM 
on cognitive functioning in children. In a meta-anal-
ysis in 2008, Gaudieri et al9 found that paediatric T1DM 
was found to be associated with poorer performance in 
learning and memory skills, as well as attention and exec-
utive function. They found that these lower cognitive 
scores were most pronounced with early-onset diabetes. 
In a further meta-analysis published in 2009 by Naguib 
et al,11 T1DM in childhood was found to be associated 
with mild cognitive impairments and mildly reduced 
overall intellectual functioning. In 2004, Desrocher et 
al12 published a review of the neurocognitive outcomes 
in children with T1DM. They reported a range of deficits 
associated with T1DM with most significant effects found 
to be related to age of disease onset, hypoglycaemia, 
duration of effects and hyperglycaemia around puberty. 
More recently in a meta-analysis in 2018, He13 found that 
glycaemic extremes associated with T1DM in childhood 
were associated with cognitive dysfunction, characterised 
by lowered intelligence, reduced attention and slower 
psychomotor speed. These findings from previous studies 
suggest a detrimental impact of T1DM in childhood on 
cognitive function, however there is less evidence whether 
this adversely impacts educational attainment in the form 
of results of high stakes examinations.
Each of the four home nations within the UK have 
made a commitment to support children and young 
people with medical conditions in school, including 
T1DM. Legislation varies across the home nations but 
all highlight the importance of support for children and 
young people with additional learning needs.14 Under 
the Equality Act 2010,15 all schools in England, Scotland 
and Wales have a duty to make reasonable adjustments to 
ensure that children and young people with a disability 
(including T1DM) are not discriminated against or put 
at a significant disadvantage to their peers. In England, 
the Children and Families Act 201416 was introduced in 
September 2014. In January 2018, the National Assembly 
for Wales voted in favour of a new Additional Learning 
Needs and Education Tribunal Act (Wales).17 In Scotland, 
there are a number of pieces of legislation regarding the 
rights of children with diabetes, in particular the Educa-
tion (Additional Support for Learning) Act 2004 (Scot-
land).18 Finally, in Northern Ireland, the Department of 
Education and Department of Health, Social Services 
and Public Safety published joint guidance entitled 
‘Supporting pupils with Medication Needs 2008’.19
As implied, both in theory and in law, T1DM has the 
potential to significantly impact children’s educational 
attainment. Therefore, assessing and analysing the 
current evidence to quantify this effect may be useful in 
assessing what and how much support and educational 
interventions should be focused on children with T1DM 
in school.
ObjECtIvEs
The primary objective of this review is to assess and analyse 
the current literature available on whether T1DM has an 
impact on educational attainment in individuals under-
taking high stakes standardised testing under 18 years of 
age at the end of compulsory schooling.
The secondary objectives include assessing the effect of 
T1DM on school attendance and educational attainment 
at other stages on the educational trajectory, if reported.
MEthOds
We have used the Cochrane Handbook for Systematic 
Reviews of Interventions20 to structure our methodolog-
ical approach, and we will report our findings using the 
recommended methods and checklist of the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA).21 This protocol was created using the 
PRISMA Protocols guidelines.22 This protocol is registered 
with PROSPERO (International Prospective Register of 
Systematic Reviews)23 at the NHS Centre for Reviews and 
Dissemination at the University of York.
Eligibility criteria
The following criteria will be used to consider inclusion 
and exclusion of studies for this review.
Type of study
We will include observational studies including prospec-
tive and retrospective cohort and case–control studies 
(and randomised controlled trials if available). We will 
exclude case series, case reports and expert opinion/
narrative reviews.
Population
We will include studies including individuals who have 
undertaken high stakes testing at the end of compulsory 
schooling when under 18 years of age.
Intervention/exposure
Known diagnosis of T1DM before undertaking high 
stakes testing at the end of compulsory schooling.
Controls/comparators
No diagnosis of T1DM before undertaking high stakes 
testing at the end of compulsory schooling. We will 
include studies using controls which allow estimates of an 
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interpretable effect size, for example, matched controls 
or population controls. We will record the type of control 
in data extraction and consider the implications in the 
review.
Outcome measures
The primary outcome will be grades obtained in high 
stakes testing at the end of compulsory schooling. 
Secondary outcomes may include school attendance and 
grades obtained at other stages on the educational trajec-
tory if reported.
Time frame
The 2015 National Institute for Health and Care Excel-
lence guidelines state that since 2004 there have been 
major changes in routine management of T1DM, aiming 
to achieve better glucose control to reduce long-term 
complications associated with the condition.24 We will, 
therefore, include studies published after the year 2004 
in order to comprehensively evaluate the most up-to-date 
available peer-reviewed and grey literature. The effect on 
educational attainment associated specifically with these 
treatment changes from 2004 may only become apparent 
at a later stage and therefore only seen in more recent or 
future studies. As a result, while it is likely that many qual-
ifying studies will use cohorts receiving treatment prior to 
this year, we will record this as part of our data extraction 
and consider this as part of the review comparison.
Setting
Included studies will be secondary school based. Studies 
including outcomes from educational tests undertaken in 
clinical or other non-school settings will be excluded.
search methods for identification of studies
We will search the following databases from January 2004 
to January 2018 and will consider only studies published 
in English.
 ► Ovid MEDLINE (1946 to present).
 ► Ovid MEDLINE Epub Ahead of Print, In-Process & 
Other Non-Indexed Citations.
 ► Ovid EMBASE (1947 to present).
 ► Thomson Reuters Web of Science.
 ► EBSCO Education Resources Information Center.
 ► EBSCO British Education Index.
 ► EBSCO Cumulative Index to Nursing and Allied 
Health Literature.
Comprehensive electronic literature search strategies 
will be used for each database. See online supplementary 
appendix 1 for the Ovid MEDLINE and Ovid EMBASE 
search strategy.
To identify additional papers, information on studies 
in progress, unpublished research or research reported 
in the grey literature will be identified through searching 
a range of relevant websites, including  diabetes. org. uk, 
and trial registers including  clinicaltrials. gov. We will 
search Electronic Table of Contents of key journals for 
relevant studies that have been published within the last 
2 years. We also plan to check review articles, reference 
lists and carry out citation tracking of included studies 
for any significant studies missed during the database 
search.
selection of studies
To select studies for further assessment, they will be 
imported and organised into Eppi-Reviewer V.4.025 and 
duplicates will be removed. Two independent reviewers 
(NO and RF) will screen the titles and abstracts of every 
record retrieved from the searches using the predeter-
mined inclusion criteria using Eppi-Reviewer V.4.0.25 
Records identified as potentially eligible on the basis 
of title and abstract will then be screened on full text 
according to set inclusion criteria. If there is any doubt 
or disagreement regarding study selection, there will 
be further discussion and, if required, involvement of a 
third reviewer (JG) to reach a consensus. Rationale for 
exclusion of studies at this stage will be documented. 
The remaining included studies will then undergo data 
extraction using a standardised pro forma. A PRISMA 
flow diagram will be used to demonstrate the number of 
included and excluded studies.
data collection
All included studies will undergo data extraction by 
two independent reviewers (NO and RF), using a stan-
dardised pro forma. The pro forma will be pilot tested 
initially to ensure consistency.
Data extracted from each study will include:
 ► Details of study, for example, first author, date of publi-
cation, country/region where study was undertaken.
 ► Details of study methodology, for example, study 
design, sample size, number of cases and controls 
included, inclusion/exclusion criteria, data linkage.
 ► Modelling strategy and covariates/confounders 
adjusted for, for example, age, gender, socioeconomic 
group, age at diagnosis, duration of diabetes.
 ► Outcomes—as stated below.
Again, any disagreements will be discussed and a third 
reviewer (JG) will be consulted if required.
Outcomes and prioritisation
Primary outcome
The primary outcome will be grades obtained in high 
stakes testing at the end of compulsory schooling. In most 
cases, we expect this to be a continuous measure assessing 
scores across a range of subjects. We anticipate there 
may be some cases where a binary measure is used, for 
example, achieving five General Certificates of Secondary 
Education (GCSEs) (grades A–C) is a commonly used 
benchmark in UK educational research.
Secondary outcomes
The secondary objectives may include school attendance 
and grades obtained at other stages on the educational 
trajectory if reported. Again, in most cases, we expect 
these to be continuous measures.
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Missing data
For any questions about eligibility or data not obtained 
from the full paper review, the authors of the papers will 
be contacted if required. If after 6 weeks no clarification 
has been provided, the study will be included in the final 
analysis and discussion, however will be identified as 
ideally requiring further information.
Assessment of risk of bias in included studies
The quality and risk of bias in the observational studies 
included in this review will be assessed using the Newcas-
tle-Ottawa Scale (NOS) for assessing the quality of 
non-randomised studies in meta-analysis.26 The NOS 
assesses cohort and case–control studies based on three 
domains:
1. Selection of study groups.
2. Comparability of study groups.
3. Ascertainment of exposure (case–control studies)/
outcome (cohort studies).
Each study can be awarded a maximum of one star 
for each numbered component within the selection and 
exposure sections and a maximum of two stars can be 
given for the comparability section, creating a maximum 
of nine stars per study. The higher the number of stars, 
the better quality the study and the lower the risk of bias.
If any randomised controlled trials are identified for 
inclusion in this review, we will assess the quality and risk of 
bias using the Cochrane Risk of Bias Tool, as described in 
the Cochrane Handbook for Systematic Reviews of Inter-
ventions.27 This tool assesses risk of bias using five main 
domains: selection bias, performance bias, reporting bias, 
detection bias and attrition bias. It allows categorisation 
of risk of bias using three main outcomes: high, low or 
unclear.
We will also specifically analyse the linkage method-
ology used in all papers included, highlighting areas of 
potential bias which may impact on the overall quality of 
the studies.
In our review, this assessment will be completed by 
two independent reviewers (NO and RF). Any disagree-
ments that cannot be resolved during moderation will be 
discussed with a third reviewer (JG).
data synthesis
We will aim to conduct a meta-analysis using a random-ef-
fects model.
The majority of the outcome data from included 
studies in our review is likely to be continuous, therefore 
the measure of effect will be analysed using standardised 
mean difference with 95% CI. Any dichotomous outcome 
data will be analysed using risk ratios or ORs which will 
also be converted into standardised mean difference with 
the appropriate transformations.
In order to not lose information, we will convert 
measures into a common metric and will aim to under-
take sensitivity analyses to look for systematic difference 
according to transformations. We will use the statistical 
software Eppi-Reviewer V.4.025 for our meta-analysis.
If possible, a sensitivity analysis will be performed to 
explore the impact of decisions made during the calcula-
tion of effect sizes, the inclusion of different study designs 
and the impact of risk of bias assessments.
If we are unable to analyse data using meta-analysis, 
we will conduct a narrative synthesis. In this case, we will 
narratively summarise and tabulate the results found 
during data extraction in order to identify patterns in 
study design and outcomes across the included studies.
Assessment of heterogeneity
We will assess heterogeneity between the included studies 
by visual assessment of forest plots (for any minimal 
overlap) and use of statistical tests including the χ2 test 
and the I2 statistic. If there is evidence of statistical hetero-
geneity, we will attempt to explore the reasons for the 
heterogeneity by using subgroup analyses based on the 
following:
 ► Patient demographics, for example, age, gender.
 ► Diabetes-specific characteristics, for example, age at 
diagnosis, haemoglobin A1c.
We will also consider a random-effects meta-regression.
Publication bias
We will examine funnel plots and conduct tests (Egger’s 
test) to assess the potential for publication bias where 
there are sufficient (>10) studies.
Quality of overall body of evidence
We will assess the quality of evidence for all outcomes 
using the Grading of Recommendations Assessment, 
Development and Evaluation system. Risk of bias, direct-
ness, precision, heterogeneity and publication bias will 
be assessed, and quality of the evidence will then be 
judged as high, moderate, low or very low. Results will 
be presented in ‘Summary of findings’ tables as recom-
mended by the Cochrane Handbook for Systematic 
Reviews of Interventions.27
Patient and public involvement
Patients were not involved in the development of this 
research question or systematic review protocol. Patients 
will not be involved in completion of the systematic review.
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